Clinical trials: Hematopoietic Stem Cells
Leukemia, Mantle Cell Lymphoma
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis.
- Conditions
- Leukemia, Mantle Cell Lymphoma, Myelofibrosis
- Trial name
- NCT00081874
- Testing
- RAD001
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
The objectives of the study are to assess the safety and tolerability of a single dose of SHP674 in Japanese participants (dose confirmation) in the tolerability assessment period of Part 1 and to assess the safety…
- Trial name
- NCT04067518
- Testing
- SHP674
- Where
- 8 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Institut de Recherches Internationales Servier
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
- Trial name
- NCT06640010
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
AML (Acute Myelogenous Leukemia), AML
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells in patients with MRD-positive AML after allo-HSCT.
- Trial name
- NCT07126782
- Testing
- Ex-vivo expanded allogeneic γδ T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Gastrointestinal Graft vs Host Disease
Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.
- Trial name
- NCT01925950
- Testing
- orBec
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Soligenix
Cytomegalovirus Infection
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants…
- Trial name
- NCT03930615
- Testing
- Letermovir
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia
Phase l/II Study of Ruxolitinib for Acute Leukemia
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease.
- Trial name
- NCT01251965
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-induced Nausea and Vomiting
The Effect of Breathing Exercise on Chemotherapy-induced Nausea and Vomiting in With Autologous Hematopoietic Stem Cell Transplantation Patients
Nausea and vomiting are serious problems in patients undergoing autologous stem cell transplantation. It is stated that the incidence of acute and delayed nausea and vomiting is more than 50%, even if the patient has been given…
- Trial name
- NCT05311371
- Testing
- Breathing exercise group, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Graft Vs Host Disease, Hematopoietic Stem Cells
Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells
Graft-versus-host disease (GVHD) is a frequent and severe complication of hematopoietic stem cell transplantation (HSC), and is responsible for significant early mortality despite prophylactic strategies developed in recent…
- Trial name
- NCT03136757
- Testing
- Transcriptomic analysis of GVHD biopsies
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY 1. Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? 2.
- Trial name
- ALL-MB 2015 (NCT03390387)
- Testing
- Dexamethasone continuous, Dexamethasone intermittent, Dexamethasone
- Where
- 58 sites in Armenia, Belarus and 3 more
- Volunteers
- 4,000 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Cirrhosis, Liver
Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis
Though the results of autologous CD34+ cell infusion and MSC in independent studies have shown promise, yet they are yet to reach the desired long term outcome.
- Trial name
- NCT04243681
- Testing
- CD 34 and MSC infusion, Standard of care for Cirrhosis management
- Where
- India
- Volunteers
- 5 people
- Sponsor
- Asian Institute of Gastroenterology, India
Lymphoma, Small Intestine Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006009
- Testing
- visilizumab
- Where
- United States
- Sponsor
- Stanford University
Lymphoma
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005998
- Testing
- carmustine, cyclophosphamide, cytarabine
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
This study investigates cancer care delivery in adolescent and young adult patients with acute lymphoblastic leukemia. Surveying institutions, evaluating delivery of care at the patient level and seeking input from healthcare…
- Trial name
- NCT03204916
- Testing
- Discussion, Medical Chart Review, Questionnaire Administration
- Where
- 482 sites in United States, Puerto Rico
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Children's Oncology Group
Hematopoietic Stem Cell Transplantation
A Structured Peer Support Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
This randomized clinical trial is evaluating the impact of a structured peer support intervention (STEPP) on psychological distress and quality of life among patients undergoing hematopoietic stem cell transplantation.
- Trial name
- STEPP-3 (NCT07774104)
- Testing
- STEPP, Minimally Enhanced Usual Care Control
- Where
- 3 sites in United States
- Volunteers
- 350 people
- Sponsor
- Brigham and Women's Hospital
Sickle Cell Disease, Graft Versus Host Disease
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving…
- Trial name
- NCT02867800
- Testing
- Diphenhydramine, Acetaminophen, Methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Monica Bhatia
Leukemia
STI571 in Treating Patients With Recurrent Leukemia
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an effective treatment for leukemia. PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00004932
- Testing
- imatinib mesylate
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia
XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia
This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell…
- Conditions
- Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma
- Trial name
- NCT05038644
- Testing
- XmAb18968 - Dose level -1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 1
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ehab L Atallah
aGVHD
Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease
This trial employs a single-arm, single-center design, planning to enroll 25 patients diagnosed with grade II-IV aGVHD at one center. Patients meeting all inclusion criteria and no exclusion criteria will be enrolled.
- Trial name
- NCT07185633
- Testing
- Gecacitinib-Corticosteroid, Methylprednisolone sodium succinate
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Bin Gu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.